business growth, while decreasing -0.5% QoQ from higher SG&A. EBITDA margin improved to 54% from continual focus in profitable revenue, cost management, and improved device margin. AIS reported a net profit
the competition back in place with operators keeping the low-price plans afloat to attract more subscribers or defend their market share. The postpaid segment grew with the new devices launched in Q3
1,921 million decreased by 7% compared to the previous year. It derived from: • Revenues from sales and services of medical device business for the year 2019 were Baht 1,798 million decreased by 3% in
& Device sales reported at Bt9,926mn, growing 7.1%YoY from a higher device sale due to economic recovery boosted by government campaign early in the quarter compared to previous year which was still in the
device sales, offset by growth in all core businesses. The total revenue increased by 2.9% QoQ driven by the launch of iPhone15. Core service revenue (excluding IC and NT partnership) recorded at
continued offering low-end unlimited data plans in both prepaid and postpaid segments in order to maintain customer base and expand market share. Hence, mobile revenue slightly declined by 0.7% YoY to
Distribution of Newly Issued Shares and Share Warrants by Issuer
, medical device business is expected to be growth at an average rate of 8.5-10.0% per year. This growth will be supported by: (i) government policy, focused on promoting investment in the sector through the